Abstract:Evaluation of: Lu KV, Chang JP, Parachoniak CA et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22(1), 21-35 (2012). In glioblastoma, a well-characterized angiogenic target is VEGF. Bevacizumab is a humanized monoclonal antibody that binds to VEGF and was developed to inhibit the VEGF signaling pathway. Based on promising results from clinical trials that bevacizumab can prolong progression-free survival in recurrent glioblastoma patients, the US FDA granted this drug accelerated approval for the treatment of recurrent or progressive glioblastoma; however, there has been no evidence that the overall median survival of patients is prolonged. More recently, Phase II clinical trials tested bevacizumab in combination with traditional radiation and/or temozolamide in newly diagnosed glioblastoma patients and again showed prolonged progression-free survival in these patients, but overall survival was not significantly changed. More importantly, there was evidence that tumors resistant to or recurring after bevacizumab treatment often showed a more aggressive phenotype. Due to the lack of effective post-bevacizumab therapies, it has been suggested that treatment with bevacizumab not be used until patients have developed late-stage recurrent tumors. Under these circumstances, there is a timely need to uncover the mechanisms of resistance to bevacizumab. In this article, Lu et al. reported a novel mechanism whereby VEGF negatively regulates tumor cell invasion by blocking MET phosphorylation in the MET/VEGFR2 complex. They showed that inhibiting the VEGF pathway results in MET activation in VEGF-knockout mouse models and in patients after bevacuzimub treatment, and that MET knockdown blocked the invasiveness of VEGF knockout tumors, suggesting that blocking the MET pathway can prevent post-bevacizumab treatment tumor recurrence, providing a strong rationale for using a combination of MET and VEGF receptor inhibitors to treat glioblastoma patients.

De novo biosynthesis and nicotinamide biotransformation of nicotinamide mononucleotide by engineered yeast cells

Whole-cell synthesis of nicotinamide mononucleotide by recombinant Saccharomyces cerevisiae from glucose and nicotinamide

Biosynthesis of β-nicotinamide mononucleotide from glucose via a new pathway in Bacillus subtilis

Metabolic Engineering of Bacillus licheniformis for the Bioproduction of Nicotinamide Riboside from Nicotinamide and Glucose

Systematic Engineering of Escherichia coli for Efficient Production of Nicotinamide Mononucleotide From Nicotinamide

A novel pH-stat fed-batch strategy to boost the production of nicotinamide mononucleotide by high cell density fermentation

Exploring the De Novo NMN Biosynthesis as an Alternative Pathway to Enhance NMN Production

Advances in the Synthesis and Physiological Metabolic Regulation of Nicotinamide Mononucleotide

Metabolic engineering of Escherichia coli for optimized biosynthesis of nicotinamide mononucleotide, a noncanonical redox cofactor

Improvement of an enzymatic cascade synthesis of nicotinamide mononucleotide via protein engineering and reaction-process reinforcement

A native phosphoribosyltransferase, PncB, is the key NMN synthase in Bacillus subtilis

Synthesis of NMN by cascade catalysis of intracellular multiple enzymes

Design and tailoring of an artificial DNA scaffolding system for efficient production of nicotinamide mononucleotide

Technology and functional insights into the nicotinamide mononucleotide for human health

The effects of (+ -)-amphetamine sulphate on the self-selected circadian rhythm of activity and rest in the canary.

RTK inhibition: looking for the right pathways toward a miracle.

Structure-guided mining and engineering of nicotinamide riboside kinase for efficient synthesis of nicotinamide mononucleotide

Stoichiometric Regeneration of Biomimetic Nicotinamide Coenzyme Powered by Biomass Sugars via In Vitro Synthetic Enzymatic Biosystems

Recent Advances in the Chemical Synthesis of β-Nicotinamide Mononucleotide

Protein engineering of NADH pyrophosphatase for efficient biocatalytic production of reduced nicotinamide mononucleotide

Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth